Alvotech Improves Access to Capital and Streamlines Path to Expected Public Listing on NASDAQ Stock Exchange
April 19 2022: Reykjavik, Iceland — Alvotech Holdings S.A. (“Alvotech”), a global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, announced today that, subject to the completion of the announced business combination (the “Business Combination”) between Alvotech, Alvotech Lux Holdings S.A.S. (“the Company”) and Oaktree Acquisition Corp. II (NYSE: OACB.U, OACB, OACB WS) (“OACB”), a special purpose acquisition company with approximately $250 million of cash in trust sponsored by an affiliate of Oaktree Capital Management, L.P., the Company has secured a Standby Equity Purchase Agreement (“SEPA”) facility from YA II PN, Ltd (“Yorkville”) and signed a binding term sheet for a debt facility from Sculptor Capital Management (“Sculptor”).
Access to content from the Arctic Knowledge Archives is available to Passport holders only.
Arctic Today is a non-profit organization, supported by donations from readers like you. While we strongly believe in giving free access to current news for all readers, we reserve content older than one year for our supporters. All individual contributions of at least $15/month or $150/year will receive a Passport to the Arctic Knowledge Archives. Help us drive the leading non-profit editorial team dedicated to delivering context, information and analysis about events in the Arctic.
Already have a Passport? Sign in
choose your level of support and unlock your Arctic Passport.
Individual Annual
$1.00
Year
Individual Monthly
$15.00
Month
